Loading...
miR-375 induces docetaxel resistance in prostate cancer by targeting SEC23A and YAP1
BACKGROUND: Treatment options for metastatic castrate-resistant prostate cancer (mCRPC) are limited and typically are centered on docetaxel-based chemotherapy. We previously reported that elevated miR-375 levels were significantly associated with poor overall survival of mCRPC patients. In this stud...
Na minha lista:
| Udgivet i: | Mol Cancer |
|---|---|
| Main Authors: | , , , , , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
BioMed Central
2016
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5105253/ https://ncbi.nlm.nih.gov/pubmed/27832783 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12943-016-0556-9 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|